Pulmatrix (Nasdaq:PULM) announced today that all subjects completed dosing in a trial of its orally inhaled migraine treatment. Lexington, Massachusetts-based Pulmatrix is evaluating PUR3100 in a Phase 1 trial using the patented iSperse technology. All subjects completed dosing of the novel orally inhaled formulation of dihydroergotamine (DHE). The company expects Phase 1 data in the […]
Clinical Trials
Study backs automated insulin delivery system from Diabeloop
Diabeloop today announced 12-month data supporting its hybrid closed-loop DBLG1 automated insulin delivery system. Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in range and time in hypoglycemia remaining significantly low. The company said in a news release that the results, combined with trust in its algorithm, […]
Study says Abbott FreeStyle Libre reduces rate of hospitalization
Abbott (NYSE:ABT) today announce real-world data demonstrating reductions in hospitalizations associated with the FreeStyle Libre system. The RELIEF study evaluated Abbott’s FreeStyle Libre continuous glucose monitoring (CGM). The findings included the significant reduction of the rate of hospitalizations due to acute diabetes events (ADEs). This study evaluated people living with type 2 diabetes on once-daily […]
MedAlliance enrolls first patient in study of drug-eluting balloon for treating erectile dysfunction
MedAlliance announced today that it enrolled the first patient in a trial for its drug-eluting ballon in treating erectile dysfunction. Geneva, Switzerland-based MedAlliance said an 82-year-old Taiwanese man enrolled in the initial trial. It will evaluate the Selution SLR sirolimus-eluting balloon for the treatment of erectile dysfunction (ED). The Perfect-Selution FIM study includes 54 patients. […]
Lyra Therapeutics enrolls first patient in Phase 3 chronic rhinosinusitis trial
Lyra Therapeutics (Nasdaq:LYRA) announced today that it enrolled the first patient in its Phase 3 Enlighten II clinical trial. Enlighten II is evaluating the company’s LYR-210 in adult patients with chronic rhinosinusitis (CRS). Lyra’s proprietary XTreo platform delivers LYR-210. Watertown, Massachusetts-based Lyra designed the proprietary XTreo platform for precise, sustained and local delivery. The platform […]
Phase 3 trial data support Glaukos iDose eye drop alternative
Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]
Study backs RejuvenAir treatment for bronchitis from CSA Medical
CSA Medical announced today that study data support the use of its RejuvenAir system for treating chronic bronchitis. Boston-based CSA Medical designed its metered cryospray (MCS) treatment using the RejuvenAir System. RejuvenAir, a proprietary interventional liquid nitrogen spray cryotherapy system, utilize software-driven dosimetry and specialty catheter. Together, this enables the delivery of cryogen spray inside […]
Study backs next-gen Medtronic MiniMed 780G insulin pump
Medtronic (NYSE:MDT) today announced positive results from a study of its next-generation MiniMed 780G automated insulin delivery system. Results from the ADAPT study, published in The Lancet Diabetes & Endocrinology, demonstrated improved glycemic control and treatment satisfaction among users of MiniMed 780G. The MiniMed 780G system is available in more than 60 countries. It is currently […]
Study shows workplace productivity improvements with One Drop type 2 diabetes tech
One Drop today announced positive results from a trial of its digital health platform for people with type 2 diabetes. Employees using the One Drop digital diabetes management platform experienced significant productivity and functioning gains and were less likely to experience presenteeism at follow-up compared to control groups. One Drop’s platform uses AI to provide […]
PhysIQ, InCarda Therapeutics to collaborate on AFib treatment tech
PhysIQ announced today that it entered into a strategic collaboration with InCarda Therapeutics. Newark, California-based InCarda Therapeutics develops first-of-their-kind inhaled therapies for treating cardiovascular diseases. Get the full story at our sister site, MassDevice.
